MORGANTOWN, W.Va. – The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer.
Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and combinations of the cancer medications pegylated liposomal doxorubicin (PLD), atezolizumab, and bevacizumab in the treatment of ovarian cancer.
“We are excited to bring this clinical trial to West Virginia and the WVU Cancer Institute,” Dr. Galvan Turner said. “This treatment has the potential to allow for more options for patients for whom other treatments may not be effective.”
The clinical trial is open to epithelial ovarian cancer patients whose cancer recurred less than one year after completing their first treatment or line of chemotherapy and are considered platinum resistant.
All participants will receive treatment, but the types of treatment will be randomly assigned.
“The WVU Cancer Institute is dedicated to expanding the field of knowledge of cancer treatment,” Galvan Turner said. “We hope this study will help advance the field and provide more options for patients with ovarian cancer.”
The construction of WVU Medicine’s new parking garage on Willowdale Road will cause some street closures and traffic delays in June and July.
Orthopaedic surgeons at WVU Medicine are now offering a procedure for the treatment of full thickness cartilage defects of the knee.
Highmark Blue Cross Blue Shield West Virginia and WVU Medicine announce agreement on multi-year contract
Highmark Blue Cross Blue Shield West Virginia (Highmark West Virginia) and WVU Medicine today (June 5) announced a long-term contract with WVU Medicine doctors and hospitals that will ensure access for all Blue Cross Blue Shield members in West Virginia. The contract encompasses all WVU Medicine facilities and WVU Medicine primary and specialist care practice sites across the state, as well as future facility or physician acquisitions.